STOCKHOLM, June 2, 2026 /PRNewswire/ -- Arelion today announced the expansion of its Conflict-Free Channel Program in Mexico, leveraging its extensive network to support...
CHARLOTTE, N.C., June 2, 2026 /PRNewswire/ -- Greenland Mines Ltd ("Greenland Mines" or the "Company") (Nasdaq: GRML) today announced that it has engaged WSP...
New Integrated DRP Capabilities powered by SOCRadar Combine External Visibility with Live Threat Context to Trigger Automated Defensive Actions in Real TimeNEW YORK, June...
BELGRADE, Serbia, June 02, 2026 (GLOBE NEWSWIRE) -- International crypto entertainment platform 1win has officially announced the signing of the full Tundra Esports Dota 2 roster. Effective June 1, professional players Pure, bzm, 33, Ari, and Whitemon compete under the 1win Team tag. Alongside the players, coach MoonMeander, esports analyst degaz, team manager Jamba, and sports director SweetyPotz are joining the organization.
Dubai and New York, June 2, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), today announces the successful closing of a USD 1.4 billion dual-tranche senior unsecured notes offering (the “Offering”) by its subsidiary VEON Midco B.V. (the “Issuer”). The Offering refinances substantially all of VEON’s debt maturing in 2027 ahead of schedule and reflects sustained confidence in VEON’s digital operator transformation and AI1440 strategy.
Nedenfor følger informasjon om transaksjoner foretatt under andre transje av Equinor ASAs (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO) tilbakekjøpsprogram for 2026.
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST.
In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...